October 30th 2024
Jonathan D. Spicer, MD, PhD, FRCS, discusses surgical considerations for patients with for resectable NSCLC after the approval of perioperative nivolumab.
November 9th 2022
The panel shares the data that excited them the most from ESMO 2022, and what to look forward to in the future.
November 2nd 2022
Recommendations for community hospitals and physicians on the critically necessary molecular tests needed for patients with NSCLC.
Drs Spicer and Sabari explain if and when they test patients with NSCLC for EGFR mutations after surgical resection.
October 26th 2022
Key opinion leaders share their thoughts on data updates from the ADUARA trial on the use of osimertinib as an adjuvant therapy for NSCLC.
Drs Bill W. Loo and Joshua Sabari discusses whether there is a role for any adjuvant therapies in NSCLC treatment, and which patients might benefit.
October 19th 2022
Joshua Sabari, MD, describes which stage groups of patients with NSCLC should receive neoadjuvant therapies, and which therapies are typically used.
Drs Wakelee, Sabari, and Wistuba review updated data on neoadjuvant treatment in NSCLC from key studies including CheckMate-816 and NADIM-2.
October 17th 2022
The panel reviews updates in the treatment of stage I-IIIA NSCLC and discusses its impact in clinical practice.
Ignacio Wistuba, MD, leads the discussion on the role of liquid biopsies for molecular testing in early NSCLC.
October 5th 2022
Jonathan Spicer, MD, explains the role of molecular testing in patients with stage I-IIIA NSCLC, and how it informs treatment decision-making.
A panel of lung cancer experts provides an overview of molecular testing in early-stage non-small cell lung cancer (NSCLC) and recommendations for biomarkers to test for and at what treatment stages to perform testing.
August 20th 2021
Jonathan Spicer, MD, PhD, discusses the efficacy observed with neoadjuvant nivolumab plus platinum-doublet chemotherapy in patients with resectable non–small cell lung cancer.